Create a clinical practice guideline using the latest type 2 diabetes mellitus management recommendations.

Clinical Practice Guideline for Type 2 Diabetes Mellitus Management

Initial Assessment and Treatment Planning

Reevaluate medication plans and medication-taking behavior every 3-6 months, adjusting based on specific patient factors that impact treatment choice 1.

Person-Centered Decision-Making Framework

When selecting pharmacologic agents, prioritize the following factors in order 1:

• Cardiovascular and renal comorbidities (most critical for mortality reduction)
• Effectiveness in achieving glycemic targets
• Hypoglycemia risk
• Impact on weight
• Cost and access barriers
• Adverse reaction profile and tolerability
• Individual patient preferences

Pharmacologic Treatment Algorithm

Step 1: Initial Therapy Selection

Consider early combination therapy at treatment initiation to shorten time to individualized glycemic goals 1.

For patients without established cardiovascular or kidney disease 1:

• Select agents addressing both glycemic AND weight goals simultaneously
• Prioritize medications with weight-neutral or weight-loss properties

Step 2: Comorbidity-Directed Therapy (HIGHEST PRIORITY)

Heart Failure (HFrEF or HFpEF)

Use SGLT2 inhibitors for glycemic management AND prevention of heart failure hospitalizations 1.

Chronic Kidney Disease

For eGFR 20-60 mL/min/1.73 m² and/or albuminuria 1:

• SGLT2 inhibitor is mandatory for minimizing CKD progression, reducing cardiovascular events, and reducing HF hospitalizations
• Note: Glycemic benefits diminish at eGFR <45 mL/min/1.73 m²

For advanced CKD (eGFR <30 mL/min/1.73 m²) 1:

• GLP-1 RA is preferred due to lower hypoglycemia risk and cardiovascular event reduction

Step 3: Intensification Strategy

When Glycemic Goals Not Met

Subsequent agent selection must address 1:

• Individualized glycemic targets
• Weight management goals
• Other metabolic comorbidities
• Hypoglycemia risk profile

GLP-1 RA vs Insulin Decision Point

GLP-1 RA (including dual GIP/GLP-1 RA) is strongly preferred over insulin 1.

Initiate insulin immediately if ANY of the following 1:

• Evidence of ongoing catabolism (unexpected weight loss)
• Symptoms of hyperglycemia present
• A1C >10% (>86 mmol/mol)
• Blood glucose ≥300 mg/dL (≥16.7 mmol/L)

If insulin is required, always combine with GLP-1 RA (including dual GIP/GLP-1 RA) for superior glycemic control, weight benefits, and reduced hypoglycemia 1.

Step 4: Weight Management Integration

When individualized weight goals are not achieved, add 1:

• Intensified lifestyle modifications
• Structured weight management programs
• Additional pharmacologic agents for weight
• Metabolic surgery evaluation (as appropriate)

The glucose-lowering treatment plan must incorporate approaches supporting weight management goals 1.

Treatment Effectiveness Principle

Use pharmacological strategies providing sufficient effectiveness to achieve AND maintain intended treatment goals 1.

System-Level Implementation Requirements

Team-Based Care Structure 1

• Coordinate between diabetes care and education specialists, dietitians, psychologists
• Integrate multiple medical specialties (primary care, endocrinology, ophthalmology, nephrology)
• Establish enhanced communication technology for engagement

Quality Improvement 1

• Implement continuous quality improvement interventions tailored to local settings
• Provide continuing education on type 2 diabetes management for all healthcare team members
• Establish accountability mechanisms for health professionals with focus on training and practice evaluation

Access and Equity 1

• Policy makers must ensure evidence-based interventions are available and affordable to all populations
• Address care delivery questions: How, where, and by whom is care delivered
• Establish governance arrangements for coordination of care processes

Common Pitfalls to Avoid

• Do not delay SGLT2 inhibitor initiation in patients with heart failure or CKD—these are mortality-reducing interventions 1
• Do not use insulin as first-line when GLP-1 RA options are available, unless meeting urgent criteria 1
• Do not ignore weight management as a parallel treatment goal to glycemic control 1
• Do not prescribe SGLT2 inhibitors for primary glycemic benefit at eGFR <45 mL/min/1.73 m²—use for renal/cardiac protection instead 1